Healthcare provider profile · identity verified

Brianna Raghunath

Nurse Practitioner · EL PASO, TX · NPI 1972268399

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	243	125
Amlodipine Besylate	Amlodipine Besylate	163	87
Metformin Hcl	Metformin Hcl	154	78
Lisinopril	Lisinopril	127	72
Levothyroxine Sodium	Levothyroxine Sodium	119	64
Omeprazole	Omeprazole	117	69
Gabapentin	Gabapentin	104	68
Losartan Potassium	Losartan Potassium	83	44
Januvia	Sitagliptin Phosphate	72	38
Fluticasone Propionate	Fluticasone Propionate	66	47
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	27
Albuterol Sulfate Hfa	Albuterol Sulfate	55	40
Hydrochlorothiazide	Hydrochlorothiazide	54	27
Trulicity	Dulaglutide	53	22
Tramadol Hcl	Tramadol Hcl	51	26
Meloxicam	Meloxicam	50	31
Rosuvastatin Calcium	Rosuvastatin Calcium	49	28
Sertraline Hcl	Sertraline Hcl	49	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	45	42
Glipizide	Glipizide	45	23
Furosemide	Furosemide	44	28
Carvedilol	Carvedilol	42	20
Azithromycin	Azithromycin	39	36
Famotidine	Famotidine	39	24
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	39	21
Acetaminophen-Codeine	Acetaminophen With Codeine	36	14
Ibuprofen	Ibuprofen	36	26
Trazodone Hcl	Trazodone Hcl	36	16
Clonazepam	Clonazepam	35	suppressed
Montelukast Sodium	Montelukast Sodium	35	18
Ozempic	Semaglutide	35	16
Simvastatin	Simvastatin	35	18
Buspirone Hcl	Buspirone Hcl	32	18
Methylprednisolone	Methylprednisolone	32	32
Tamsulosin Hcl	Tamsulosin Hcl	32	17
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	31	28
Prednisone	Prednisone	31	27
Tizanidine Hcl	Tizanidine Hcl	31	24
Duloxetine Hcl	Duloxetine Hcl	30	17
Ciclopirox	Ciclopirox	27	15
Mupirocin	Mupirocin	27	26
Celecoxib	Celecoxib	26	18
Doxycycline Monohydrate	Doxycycline Monohydrate	26	26
Alendronate Sodium	Alendronate Sodium	25	15
Metoprolol Succinate	Metoprolol Succinate	25	16
Pioglitazone Hcl	Pioglitazone Hcl	25	18
Pantoprazole Sodium	Pantoprazole Sodium	24	16
Doxycycline Hyclate	Doxycycline Hyclate	23	22
Vitamin D2	Ergocalciferol (Vitamin D2)	22	13
Glimepiride	Glimepiride	21	suppressed
Alprazolam	Alprazolam	20	15
Allopurinol	Allopurinol	19	11
Amoxicillin	Amoxicillin	19	19
Diclofenac Sodium	Diclofenac Sodium	19	11
Finasteride	Finasteride	19	suppressed
Cefuroxime	Cefuroxime Axetil	18	15
Chlorthalidone	Chlorthalidone	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Jardiance	Empagliflozin	17	11
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	12
Naproxen	Naproxen	17	11
Ammonium Lactate	Ammonium Lactate	16	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	15
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	13
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Bydureon Bcise	Exenatide Microspheres	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Nystatin	Nystatin	15	13
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Eliquis	Apixaban	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error